SCYNEXIS (NASDAQ:SCYX) posted its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.04, Fidelity Earnings reports. SCYNEXIS had a negative net margin of 8,592.97% and a negative return on equity of 102.52%. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.06 million.
Shares of NASDAQ SCYX traded down $0.13 during midday trading on Friday, hitting $1.45. The company’s stock had a trading volume of 25,707 shares, compared to its average volume of 1,395,365. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.53 and a current ratio of 4.53. SCYNEXIS has a 1 year low of $0.35 and a 1 year high of $2.15. The firm has a market cap of $66.96 million, a price-to-earnings ratio of -1.47 and a beta of 2.34.
Several research firms have recently commented on SCYX. Zacks Investment Research lowered shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. ValuEngine lowered shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Tuesday, December 25th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. SCYNEXIS currently has an average rating of “Buy” and an average price target of $4.81.
ILLEGAL ACTIVITY WARNING: “SCYNEXIS (SCYX) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/03/15/scynexis-scyx-posts-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Read More: What economic reports are most valuable to investors?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.